human factor B produced by monocytes and hepatoma cells are similar to those of factor B purified from serum (7, (25) (26) (27) . The high molecular weight forms of cellular factor B antigens that have been described (27) may be artifactual.
In response to developmental and environmental signals, mononuclear phagocytes display a variety of functional states characterized by differences in morphology, surface antigens, and protein secretion. Whereas some proteins, such as lysozyme, are secreted constitutively, others, such as apolipoprotein E (ApoE), vary according to the inflammatory state of the macrophage (28) .
In this report we show that the major constitutive Mr 90,000-93,000 glycoprotein synthesized and secreted by mouse peritoneal macrophages is factor B, and that this protein is active in the complement system. In addition, we have compared the conditions under which ApoE and factor B are synthesized by macrophages.
Materials and Methods

Human Complement Proteins and Antibody to Human Complement Factor B.
We prepared human complement proteins factor B (29) , factor Bb (20, 29) , factor D (30) , and cobra venom factor (CVF) (31) as described previously. Factor B was radiolabeled with 1~5I by the method of Bolton and Hunter (32) , and factor Bb was labeled by the Iodogen (Pierce Chemical Co., Rockford, IL) method of Fraker and Speck (33) . Specific rabbit antibody directed against factor B was prepared by affinity chromatography on Sepharose (CNBrSepharose; Pharmacia Fine Chemicals, Piscataway, NJ) containing covalently bound factor B antigen. Adsorbed Ig were eluted with 0.1 M acetate-buffered, 0.14 M saline, pH 2.5, containing 0.02 M EDTA, into 0.2 M Tris-buffered 0.14 M saline, pH 8.0.
Preparation of Mouse Plasma. We collected normal mouse plasma from ICR mice by retroorbital puncture into citrate phosphate dextrose at a final citrate concentration of 20 raM. Phenylmethylsulfonyl fluoride (PMSF) was added as a proteinase inhibitor at a final concentration of 5 mM. This normal mouse plasma was stored at -70°C until used. Alternatively, normal mouse plasma frozen in acid citrate dextrose was purchased from Pel-Freez Biologicals, Rogers, AR, and PMSF was added to a final concentration of 5 mM when the sample was thawed. We also collected fresh normal mouse plasma from BALB/c mice by cardiac puncture.
Purification of Mouse Factor Bb. We purified mouse factor Bb from normal mouse plasma by affinity chromatography on a 2 ml CNBr-Sepharose column containing 1 mg of affinity-purified anti-human factor B Ig. Mouse factor B was eluted with glycine-HC1 buffer, pH 2.5, into Tris-HCI, pH 8; 106 + 16/zg (mean -+ SD; n = 4) of factor B antigen was isolated per milliliter of normal mouse plasma. Assuming a factor B concentration of 160 #g]ml in this plasma (as measured by radioimmunoassay [RIA]), the apparent recovery of protein in this step was 62 + 3% (n --4) by this column chromatographic method. We analyzed mouse factor B by nonreducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (34) .
Factor B RIA. We developed a double-antibody equilibrium RIA specific for factor B. Human factor B (50 #g) was radiolabeled with 1 mCi ~25I-labeled Bolton-Hunter reagent (32) (Amersham Corp., Arlington Heights, IL) to a final specific activity of 6-9 × 105 cpm/#g. Over 90% of radiolabeled factor B was precipitated with 10% trichloroacetic acid; >95% of cpm were Mr 90,000, as assessed by SDS-PAGE (6% acrylamide) (35) , and >90% of cpm had a sedimentation rate of 5-6 S, as assessed by sucrose density gradient ultracentrifugation. Dilutions of all reactants were made in 0.1 M Tris-HCI, 0.14 M NaCl, pH 7.2, containing 2% heat-inactivated normal rabbit serum. The assay consisted of three compartments: (a) 250 #1 t~5I-labeled factor B (0.5 nM); (b) 250 #1 affinity-purified rabbit anti-factor B Ig (diluted 1:1500); and (c) 250 ul of a competitor. After 18 h at 4°C, 250 el of goat anti-rabbit Ig was added, and allowed to react for 5 h at 4°C. The immunopre-cipitates formed were removed by centrifugation (I ,200 g for 30 min), and an aliquot of the supernatant (750 ~l) was removed and counted to determine (by difference) the radioactivity bound in the immunoprecipitate.
Mouse Peritoneal Macrophages. We collected macrophages by lavage from the peritoneal cavities of CD-1, C3H/HeN (Charles River Breeding Laboratories, Inc., Wilmington, MA), and C3H/HeJ (The Jackson Laboratory, Bar Harbor, ME) strains of mice injected 12 d previously with 2-6 x 106 viable mycobacteria of strain bacillus Caimette-Guerin (BCG), or 4 d previously with 1 ml of Brewer's thioglycollate broth (Difco Laboratories, Detroit, MI), 25 mg/kg of pyran copolymer (a gift of Hercules Inc., Wilmington, DE), 0.5 ml of 5 mM NalO4, 10-30/~g of detoxified LPS from Salmonella typhimurium, or 1 mg Corynebacterium parvum (RIBI Immunochem, Hamilton, MT) (36, 37) . We plated macrophages at a density of 5 × 10 s cells in 2 cm ~ in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated (56°C, 30 min) fetal bovine serum (FBS) for 2 h at 37°C in an atmosphere of 95% air and 5% CO2. Nonadherent cells were removed by washing, and adherent cells were placed in serum-free medium containing 0.2% lactalbumin hydrolysate. We prepared macrophage cellular extracts by washing the cell monolayer three times with 0.15 M NaCI and then scraping, in the presence of 0.1% Triton X-100, to remove cells. We stored lysates and medium samples at -20°C until used.
Mouse Bone Marrow-derived Macrophages. We flushed cells from mouse femurs with Hanks' balanced salt solution, then grew them in medium containing 10% FBS, 10% horse serum, and 10% L cell-conditioned medium (38, 39) . The mouse macrophage line P388D 1 was cultured as described previously (39) .
Radiolabeling of Proteins. We incubated macrophages with [35S]methionine, and analyzed secreted and cellular proteins by SDS-PAGE using the Laemmli buffer system (34, 36, 40) . For radiolabeling of secreted macrophage serine esterases, we treated conditioned medium (CM) from thioglycollate-elicited macrophages with [3H]diisopropyifluorophosphate (DFP) (New England Nuclear, Boston, MA), essentially as described previously (41) .
lmmunoprecipitation of Factor B from Mouse Macrophages. Radiolabeled proteins in macrophage-conditioned medium or cell lysates were immunoprecipitated according to a modification (36, 41) of the Jones procedure (42) . Briefly, we prepared cell lysates by scraping cells into phosphate-buffered saline containing 0.5% Nonidet P-40, 2 mM methionine, and 0.02% NaNs (SAC buffer). CM was centrifuged to remove any cellular debris before preadsorption for 15 min on ice with 60 #g of rabbit anti-bovine serum albumin (anti-BSA) IgG (Cappei Laboratories, Cochranville, PA) per milliliter of sample and 150-200 #1 of 10% Staphylococcus aureus suspension (Zysorbin; Zymed Labs, Burlingame, CA). The Zysorbin had been washed three times in SAC buffer, and resuspended in SAC buffer containing 1 mg/ml of ovalbumin. We then immunoprecipitated the preadsorbed samples for 30 min at 25°C with 10 #g rabbit anti-human factor B. Nonimmune IgG was used as a control. After immunoprecipitation, we added 200 #! of S. aureus suspension and allowed it to react for 20 min on ice. We centrifuged the samples and washed the pellets twice with SAC-ovalbumin buffer, once with SAC buffer, then resuspended them in Laemmli sample buffer, and boiled them in a water bath before electrophoresis. ApoE was identified by immunoprecipitation, and fibronectin was identified by binding to S. aureus (36) . Factor B in macrophage secretions was also identified by immunoblotting onto nitrocellulose filters (43) essentially as described previously for ApoE (36) .
Conditions for Activation of Macrophage Factor B. We studied the functional properties in the complement system of mouse macrophage factor B by testing for the ability of the protein to form a complex with CVF, in which factor B is cleaved by factor D. We incubated samples of media or cell extracts (100 #1) for 60 min at 37°C with 10 #g CVF, 16 #g of factor D, 4 mM MgCI2, and 0.02 mM CaCI~. After this incubation, we precipitated activated factor B antigens from the incubation mixture by rabbit anti-human factor B, and analyzed them by SDS-PAGE.
Results
Purification of Mouse Plasma Factor Bb. Mouse plasma factor B exhibited two or three polypeptides with apparent Mr of 60,000-65,000 under nonreducing conditions in SDS-PAGE; these polypeptides comigrated with human factor Bb produced by activation of purified factor B with C3b and factor D (Fig. 1) . Under reducing conditions, with dithiothreitol, both mouse and human factor Bb migrated in SDS-PAGE as a single polypeptide species, suggesting that the three bands observed under nonreducing conditions may be due to slight heterogeneity in either the detergent binding or polysaccharide composition of Bb. The size of the polypeptides indicates that mouse factor Bb, and not native factor B, is the primary product of this purification procedure.
In the factor B RIA, purified factor B and normal human serum competed with a typical dose response (Fig. 2 a) . Purified factor D, C3, C5, human albumin, or serum immunochemically depleted of factor B did not compete, indicating the specificity of the assay (data not shown). The cross-reaction of mouse factor B with antibody to human factor B is shown in Fig. 2b . At a dilution of 1:96, normal mouse plasma inhibited the binding of anti-human factor B to ~25I-labeled factor B to a maximum of 10-15% (Fig. 2 b) . We calculated the apparent concentration of factor B antigen in normal mouse plasma to be 120-180 #g/ml (in human factor B antigenic equivalents). FBS, calf serum, goat serum, and normal rabbit serum containing hemolytically active factor B did not significantly compete with human factor B at dilutions of 1:50 to 1:500 (<4% inhibition).
Identification of Factor B as a Major Protein Secreted by Mouse Macrophages.
The CM from BCG-elicited macrophages incubated with [35S]methionine contained two prominent, newly synthesized polypeptides migrating as a doublet of Mr 90,000 and 93,000 in SDS-PAGE. They were identified as complement factor B by their comigration with purified human serum factor B, immunoprecipitation with affinity-purified antibodies from antisera raised to human factor B, Western immunoblotting, and mapping of the products of partial digestion with chymotrypsin (Fig. 3) . In addition, factor B is a serine proteinase that is weakly labeled after incubation with [3H]DFP (44) . When macrophage-conditioned culture medium was incubated with [SH]DFP and then analyzed by SDS-PAGE, the prominent Mr 90,000 macrophage polypeptide was weakly labeled with [3H]-DFP, although there was strong labeling of many other polypeptides (data not FIGURE 1. Comparison of 6% SDS-PAGE of purified mouse factor Bb (3 and 4) with purified human factor B (I and 5) and factor Bb (2). shown). Thioglycollate-elicited macrophages were collected by lavage of the peritoneal cavity, and immediately placed in suspension with [~SS]methionine. Synthesis and secretion of factor B were detectable by immunoprecipitation, remaining at the same rate for the first 6 h in culture (data not shown). Factor B was first detected in the medium of thioglycollate-elicited macrophages after 30-60 rain of continuous radiolabeling, reaching a constant rate of secretion after 2 h, remaining linear for ~6 h, and still increasing after 24 h (Fig. 4) . Factor B represented ~0.5% of total cellular protein synthesized at 0.5 h of labeling. Intracellular factor B reached a plateau after 3-4 h of labeling and then remained constant at about the level of factor B secreted in a 2 h period. In (36, 37, (45) (46) (47) . Nonspecifically elicited and immunologically activated peritoneal macrophages display distinct patterns of protein secretion immediately after explanting, and some differences are maintained after culture for several days (36) . However, newly synthesized factor B was a constant proportion of the total secreted proteins from 2 to 72 h in culture, and did not significantly differ in thioglycollate-, NaIO4-, BCG-, or pyran copolymerelicited macrophages (Table I) . T h e amount of factor B in the cell extracts and culture medium o f mouse macrophages elicited by a variety o f stimuli was quantified by equilibrium RIA (Tables II and III) . T h e cell lysates contained 2 -4 nmol factor B per 5 x 105 cells (Table II) , and medium samples contained 2 - 10 nM factor B (Table III) . Medium obtained from P388D1, a continuous mouse macrophage cell line, contained similar amounts of factor B antigen; however, medium from L cells (a continuous fibroblast cell line) contained <0.01 nM factor B (Table III) .
Activation of Macrophage Factor B to Factors Bb and Ba. The complement system activity of the prominent biosynthesized factor B (Mr 90,000 and 93,000) polypeptides in CM was investigated by studying conversion of factor B to factor Bb (M,. 60,000-65,000) and Ba (Mr 30,000-38,000) activation fragments.
[35S]-Methionine-labeled secretion products of thioglycollate-elicited or BCG-activated peritoneal macrophages were incubated with CVF, factor D, and Mg+÷; and factor B was immunoprecipitated by affinity-purified antibody against human factor B. SDS-PAGE showed biosynthetically labeled molecular species of apparent Mr 93,000, 90,000, 65,000, 63,000, 60,000, 38,000, 36,000, and 30,000 (Fig. 5) . These polypeptides were not precipitated by nonimmune serum or by Macrophages (5-10 x l0 S cells/well) were cultured for 24 or 48 h in 1 ml of serum-free medium; for the peritoneal macrophages, this began 2 h after explanting into culture. Macrophages were obtained from either CD-1 or C3H/HeN mice. Each type of culture, in duplicate or triplicate, was assayed at three dilutions in the factor B RIA. Data are expressed in equivalents of human factor B (mean + SD). tides. These molecular sizes correspond to the sizes of purified factor Bb ( Fig. 1) and Ba activation fragments.
Distinct Phenotypes for the Synthesis and Secretion of Factor B, ApoE, and Fibronectin by Macrophages in Culture.
Thioglycollate-elicited macrophages synthesized and secreted detectable factor B, ApoE, and fibronectin at 2 and 72 h of culture (Fig. 6) . In contrast, macrophages elicited with pyran copolymer synthesized only factor B at 2 h, and synthesized ApoE after culture for 72 h, while their secretion of factor B decreased somewhat. They did not synthesize fibronectin (Fig. 6) .
During the culture of bone marrow-derived cells in the presence of L cellconditioned medium, mononuclear phagocyte precursors serially express the differentiated properties of monocytes and macrophages, including protein secretion (39) . Secretion of factor B was detectable by day 5, and remained at approximately the same relative rate through day 14 of culture ( Fig. 7) . In contrast, ApoE secretion did not commence until day 9 ( Fig. 7) (39) . Thus, factor B expression appears relatively early during the development of these cells from bone marrow precursors, and is constitutive by the monocyte and immature macrophage stages.
Modulation of Macrophage Factor B Secretion by LPS.
There is evidence, based on hemolytic assays, that macrophage factor B activity is increased after treatment Resident peritoneal macrophages (5 × 105 cells/well) from C3H/HeN mice were placed in serum-free medium containing 0-100 ng/ml of LPS for 24 h, in duplicate to quadruplicate cultures. Each medium sample was assayed at three dilutions in the human factor B RIA. Data are expressed in equivalents of human factor B (mean 4-SD).
o f cells with LPS (24) . I n the p r e s e n t study, Treatment of macrophages from the endotoxin-resistant C3H/HeJ mouse strain (37) in culture with as much as 10 #g/ml of LPS increases factor B accumulation by less than twofold. In contrast, LPS decreases ApoE secretion (37) . Discussion Our data indicate that the major Mr 90,000-93,000 polypeptides synthesized by mouse macrophages in culture are factor B of the complement system. This glycoprotein is recognized to be the serine proteinase active in the alternative pathway of complement activation. The Bb activation fragment is, as has recently been shown, biologically active in inducing macrophage spreading (19, 20) , intracellular killing (22, 23) , and lymphocyte blastogenesis (48) . Macrophages may also bind factor B to their surfaces (49) . The results presented here provide physical evidence and quantitative data that confirm and extend earlier observations, based largely on measurements of hemolytic activity, that factor B is synthesized by macrophages (4-6, 24, 27). Our findings also indicate that a large percentage of factor B synthesized by macrophages is hemolytically active in the complement system, because biosynthetically radiolabeled factor B was cleaved after the addition of purified CVF, factor D, and Mg ÷+.
Several lines of evidence support these conclusions. First, the radiolabeled polypeptides of Mr 60,000-65,000 and 30,000-38,000, sometimes detected in immunoprecipitates from macrophage extracts and culture medium, may be the endogenous factor B activation fragments, factor Bb and factor Ba, respectively. Antibody prepared to factor B specifically precipitated biosynthetically labeled polypeptides of Mr 90,000-95,000, 60,000-65,000, and 30,000-38,000 from the medium and cellular extracts of mouse macrophages. Second, biosynthetically labeled Mr 90,000 and 93,000 polypeptides in macrophage culture medium decreased after complement activation in the medium by the addition of CVF and purified factor D, with a concomitant increase in the smaller Mr 60,000-65,000 CBb-like") and Mr 30,000-38,000 ("Ba-like") activation fragments. Immunochemical comparison by RIA of macrophage-associated factor B antigens and purified factor B showed that these polypeptides share common epitopes, indistinguishable in RIA analyses. The finding that the P388D 1 macrophage cell line synthesized factor B while cultured in serum-free medium adds additional support to the interpretation that factor B is a biosynthetic product of macrophages and not of some other possible contaminating cell type. Finally, factor B accumulated in the CM of mouse macrophages to 10 nM (600 ng/ml) and was present in cell extracts at 4-8 nmol/106 cells, as determined by RIA.
Resident macrophages and macrophages elicited with the nonspecific inflammatory agent, thioglycollate, synthesize ApoE, but those elicited with pyran copolymer do not, suggesting that synthesis of ApoE is repressed during cellular activation (36) . In contrast, factor B was synthesized, secreted, and accumulated in the medium of resident peritoneal macrophages, macrophages elicited with thioglycollate, and macrophages activated with pyran copolymer or BCG. We found no significant difference in the concentration of factor B in the medium at 24 or 48 h when peritoneal macrophages were collected from mice injected with thioglycollate, BCG, LPS, or C. parvum. Factor B was also present in the medium of mouse bone marrow-derived mononuclear phagocytes at 5 d in culture, an early monocytic stage in their maturation, whereas ApoE secretion began only after 9 d. These data suggest that factor B is a constitutive product of macrophages. However, the synthesis of factor B could be modulated by certain signals, because treatment of macrophages with LPS resulted in an increase both in synthesis rate and in the concentration of factor B in the medium. We also noted that, after 72 h in culture, macrophages activated in vivo by BCG and pyran copolymer decreased their rates of secretion of factor B as their activated state was lost (36) . This is in keeping with a recent observation that "r-interferon stimulates factor B synthesis (Z. Werb, unpublished data).
Although these experiments have established that the proenzyme factor B is secreted in prodigious amounts by macrophages, the immunoprecipitation patterns suggest that conversion of factor B to the active form, Bb, occurs slowly, if at all, in culture, raising questions about the events that may be required to activate macrophage-derived factor B to Bb. The cellular proteinases mediating activation of factor B are, at present, unknown; however, trypsin (59), plasmin (30) , kallikrein (51) , and factor D (in the presence of C3b) (30) have been shown to cleave and activate factor B in an experimental system of purified proteins. Because factor D and C3 are synthesized by macrophages (1, 2, 4, 5), and C3b is associated with lymphocytes (52), it is possible that these proteins and cells may act cooperatively to activate macrophage-derived factor B.
To assess the possible biological significance of macrophage-derived factor B, the relative amount of factor B synthesized by macrophages was quantified. In a previous study (20) , activated factor Bb induced macrophage spreading at concentrations of 1-30 nM in culture medium. In the present study, factor B constituted 4-6% of the total biosynthetically labeled protein secreted by macrophages. Cellular and secreted factor B concentrations, measured by RIA, were well within this range of potential biological activity; however, it is important to note that the extent of activation of factor B to Bb in these cultures was not determined. Although factor Bb is significantly less active in cleaving C3 and C5 after release from the C3b-Bb complex (53) , free factor Bb also retains a limited ability to cleave C3 and C5 in the absence of C3b (54) . These combined findings make it difficult, at present, to assess what biological role factor B may play in macrophage cultures.
It is unlikely that factor B plays a major role as a macrophage plasminogen activator (55) , because the properties of macrophage plasminogen activator (40, 56) are not similar to those of factor B. Synthesis of plasminogen activator is induced when macrophages are elicited with thioglycollate or BCG (35, 40, 56) , whereas synthesis of factor B was constitutive. Although factor Bb exhibits an apparent Km for plasminogen cleavage of 20 nM, it may be a relatively ineffective plasminogen activator, cleaving <0.8 mol of substrate plasminogen per mol of factor Bb per minute under the best experimental conditions to date (J. Sundsmo, unpublished data.).
Many bacterial, cellular, viral, parasitic, and chemical agents may activate the alternative pathway of complement. The present findings raise the possibility that macrophage-derived factor B may participate locally in certain physiologic and pathologic immune responses. Whether several cell types are necessary to activate and assemble complement proteinases of the leukocyte complement system (52) remains to be determined.
Summary
Factor B, the complement alternative pathway serine proteinase, a class III gene product of the major histocompatibility complex, is a major constitutive secretion product of mouse mononuclear phagocytes. This glycoprotein was synthesized and secreted by macrophages as a doublet of Mr 90,000 and 93,000 polypeptides that were immunoprecipitable with antibodies raised to human serum factor B, and that were indistinguishable from plasma factor B by immunoreactivity, peptide mapping, and molecular weight. Macrophage factor B was cleaved and activated to factor Bb-and Ba-like fragments by factor D and cobra venom factor. Some conversion of macrophage factor B to Bb-sized fragments occurred spontaneously in the conditioned culture medium after several hours. Factor B represented ~0.5% of newly synthesized protein and 4-6% of the secreted protein of resident peritoneal macrophages and macrophages elicited with thioglycollate broth, pyran copolymer, NalO4, bacillus Calmette-Guerin, or Corynebacterium parvum. We detected synthesis of factor B immediately upon explanting these macrophages in culture; synthesis continued for several days in culture. The rate of secretion of factor B, as a proportion of total protein secretion in culture, remained constant with time. By radioimmunoassay, factor B antigens accumulated in the 24-h macrophage-conditioned culture medium at 2-10 nM, ~md was present in cell lysates at 4-8 nmol per 106 cells. We detected synthesis of factor B in bone marrow-derived macrophages as early as 5 d of culture. The P388D1 macrophage line synthesized factor B, but mouse L cells did not. In contrast, apolipoprotein E, another secreted protein of macrophages, was secreted by resident and thioglycollate-elicited macrophages but not by freshly harvested pyran copolymer-activated macrophages. Its synthesis was initiated at day 9 in culture of bone marrow-derived macrophages. These data support the classification of factor B as a constitutive biosynthetic' and secreted protein of immature and mature macrophages in various states of activation. Production of factor B was modulated by treatment of macrophages in vivo or in culture with bacterial lipopolysaccharide endotoxin, which increased the synthesis, secretion, and accumulation of factor B up to 11-fold.
